- Home
- ACXP vs AYTU Comparison
ACXP vs AYTU Comparison
Compare ACXP & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- AYTU
- Stock Information
- Founded
- ACXP 2017
- AYTU N/A
- Country
- ACXP United States
- AYTU United States
- Employees
- ACXP N/A
- AYTU N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- AYTU Health Care
- Exchange
- ACXP Nasdaq
- AYTU Nasdaq
- Market Cap
- ACXP 8.4M
- AYTU 9.6M
- IPO Year
- ACXP 2021
- AYTU N/A
- Fundamental
- Price
- ACXP $0.47
- AYTU $2.20
- Analyst Decision
- ACXP Strong Buy
- AYTU Strong Buy
- Analyst Count
- ACXP 2
- AYTU 2
- Target Price
- ACXP $10.00
- AYTU $10.00
- AVG Volume (30 Days)
- ACXP 18.7M
- AYTU 208.6K
- Earning Date
- ACXP 08-08-2025
- AYTU 05-14-2025
- Dividend Yield
- ACXP N/A
- AYTU N/A
- EPS Growth
- ACXP N/A
- AYTU N/A
- EPS
- ACXP N/A
- AYTU N/A
- Revenue
- ACXP N/A
- AYTU $81,659,000.00
- Revenue This Year
- ACXP N/A
- AYTU N/A
- Revenue Next Year
- ACXP N/A
- AYTU $8.68
- P/E Ratio
- ACXP N/A
- AYTU $11.94
- Revenue Growth
- ACXP N/A
- AYTU 0.41
- 52 Week Low
- ACXP $0.30
- AYTU $0.95
- 52 Week High
- ACXP $3.33
- AYTU $2.88
- Technical
- Relative Strength Index (RSI)
- ACXP 52.38
- AYTU 62.85
- Support Level
- ACXP $0.45
- AYTU $2.04
- Resistance Level
- ACXP $0.59
- AYTU $2.45
- Average True Range (ATR)
- ACXP 0.08
- AYTU 0.13
- MACD
- ACXP -0.01
- AYTU 0.01
- Stochastic Oscillator
- ACXP 27.06
- AYTU 68.00
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.